Literature DB >> 7564507

Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells.

Z B Hu1, M D Minden, E A McCulloch.   

Abstract

All-trans retinoic acid (ATRA) increases the sensitivity of AML blast cells to cytosine arabinoside (Ara-C) or daunorubicin (DNR) when ATRA is given after drug. We have proposed that down-regulation of bcl-2 is part of the mechanism by which ATRA regulates drug sensitivity. To test this hypothesis cDNA encoding bcl-2 was transfected into cells of the continuous lines OCI/AML-2 and OCI/AML-5. Four transfectant lines were isolated; three contained transfected bcl-2 in the sense orientation (AML5-BCL2sa, AML5-BCL2sb and 2-bcl2) and one with anti-sense bcl-2(AML5-bcl2as). The presence of the transfected gene was demonstrated by Northern blot; translation of the sense transfected genes into protein was demonstrated by Western blotting. Lines with sense-oriented transfected bcl-2 were significantly less sensitive to Ara-C or H2O2 than the parental lines; the cells with anti-sense transfected genes were more sensitive than their parent but the difference did not reach statistical significance. The effect of ATRA on bcl-2 expression was compared in sense-transfected cells and their parents; by Northern blotting it was shown that the endogenous but not the transfected genes were down-regulated after ATRA exposure. The capacity of cells with transfected genes to respond to ATRA was tested by obtaining Ara-C survival curves for ATRA-treated cells. Compared to controls not exposed to ATRA, the transfected cells showed little or statistically insignificant changes in Ara-C sensitivity after ATRA treatment. We conclude that data from the transfectants provides evidence that expression of bcl-2 is a determinant of sensitivity to Ara-C and H2O2; and that the effect of ATRA on sensitivity requires the presence of bcl-2 genes in association with regulatory elements.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564507

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.

Authors:  C Ustün; M Beksac; K Dalva; H Koc; N Konuk; O Ilhan; M Ozcan; P Topcuoglu; D Sertkaya; M Hayran
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

3.  Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Authors:  Richard F Schlenk; Konstanze Döhner; Michael Kneba; Katharina Götze; Frank Hartmann; Francesco Del Valle; Heinz Kirchen; Elisabeth Koller; Jörg T Fischer; Lars Bullinger; Marianne Habdank; Daniela Späth; Silja Groner; Bernhard Krebs; Sabine Kayser; Andrea Corbacioglu; Andreas Anhalt; Axel Benner; Stefan Fröhling; Hartmut Döhner
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

4.  Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.

Authors:  Marie-Luise Hütter-Krönke; Axel Benner; Konstanze Döhner; Jürgen Krauter; Daniela Weber; Margit Moessner; Claus-Henning Köhne; Heinz A Horst; Ingo G H Schmidt-Wolf; Mathias Rummel; Katharina Götze; Elisabeth Koller; Andreas L Petzer; Hans Salwender; Walter Fiedler; Heinz Kirchen; Detlef Haase; Stephan Kremers; Matthias Theobald; Axel C Matzdorff; Arnold Ganser; Hartmut Döhner; Richard F Schlenk
Journal:  Haematologica       Date:  2016-04-01       Impact factor: 9.941

5.  Early Detection of t(8;21) Chromosomal Translocations During Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study.

Authors:  Walter Kleine Neto; Mariana Serpa; Sabri Saeed Sanabani; Patricia Torres Bueno; Elvira Deolinda Rodrigues Pereira Velloso; Pedro Enrique Dorlhiac-Llacer; Israel Bendit
Journal:  Clin Med Insights Oncol       Date:  2010-12-20

6.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

Authors:  Gentao Liu; Xiangpeng Yuan; Zhaohui Zeng; Patrizia Tunici; Hiushan Ng; Iman R Abdulkadir; Lizhi Lu; Dwain Irvin; Keith L Black; John S Yu
Journal:  Mol Cancer       Date:  2006-12-02       Impact factor: 27.401

7.  Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.

Authors:  A Nehmé; P Varadarajan; G Sellakumar; M Gerhold; H Niedner; Q Zhang; X Lin; R D Christen
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

8.  Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).

Authors:  Yasemin Küley-Bagheri; Karl-Anton Kreuzer; Ina Monsef; Michael Lübbert; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2018-08-06

9.  The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.

Authors:  Aziz Nazha; Carlos Bueso-Ramos; Eli Estey; Stefan Faderl; Susan O'Brien; Michael H Fernandez; Martin Nguyen; Charles Koller; Emil Freireich; Miloslav Beran; Sherry Pierce; Michael Keating; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Journal:  Front Oncol       Date:  2013-09-06       Impact factor: 6.244

10.  All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Authors:  Richard F Schlenk; Michael Lübbert; Axel Benner; Alexander Lamparter; Jürgen Krauter; Wolfgang Herr; Hans Martin; Helmut R Salih; Andrea Kündgen; Heinz-A Horst; Peter Brossart; Katharina Götze; David Nachbaur; Mohammed Wattad; Claus-Henning Köhne; Walter Fiedler; Martin Bentz; Gerald Wulf; Gerhard Held; Bernd Hertenstein; Hans Salwender; Verena I Gaidzik; Brigitte Schlegelberger; Daniela Weber; Konstanze Döhner; Arnold Ganser; Hartmut Döhner
Journal:  Ann Hematol       Date:  2016-10-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.